Sinovac Biotech (SVA) said late Thursday it received a notification from Nasdaq informing the Chinese biopharmaceutical company of non-compliance with a listing rule related to the delayed filing of its 2024 annual report.
The company has until July 15 to submit a plan to regain compliance. If Nasdaq accepts the plan, Sinovac could be granted an extension until Nov. 11 to regain compliance.
The company's audit committee is "actively searching" for a new auditor following the previously disclosed resignation of Grant Thornton Zhitong Certified Public Accountants.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.